Biotech company Eradivir closes $10.25M Series A funding round to complete Phase 2a study of influenza therapeutic
25. September 2024 10:00 ET
|
Purdue Research Foundation
WEST LAFAYETTE, Ind., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round. The...